The choice in plain terms

If you have been told you need ACI for a significant cartilage defect, the first practical question is rarely about biology — it is about operations. Standard ACI and its more modern variant, MACI, both require two separate trips to theatre: one to harvest a small cartilage sample, and a second, weeks later, to implant the repaired cells. That two-stage structure is the norm most consultants still follow.

STACI — Single-Treatment Autologous Chondrocyte Implantation — is a direct challenge to that norm. It aims to carry out both steps within a single continuous sitting, harvesting and processing the cells intraoperatively before implanting them the same day. The biological reasoning behind that approach is credible and well-articulated in the scientific literature.

What it is not, yet, is the established standard. The evidence supporting STACI is promising but early, and no large randomised trial has yet compared it head-to-head with two-stage ACI or MACI. This article maps what is known, what remains investigational, and what that distinction means for a patient deciding between these pathways today.

Two-stage ACI as the evidence baseline

Thirty years of published outcomes give two-stage ACI its authority. Endorsed in the UK by NICE technology appraisal TA477 and cleared by the FDA for femoral condyle and patella defects, the procedure demonstrates successful results in around 82% of patients over the long term — rising to 92% for isolated lesions. It is indicated for symptomatic, full-thickness damage (ICRS grade III–IV) in defects typically between 2 and 10 cm², where an intact surrounding cartilage rim can support the graft.

MACI updated the delivery format — cells are pre-seeded onto a type I/III collagen scaffold rather than injected under a sutured periosteal flap — but the two-visit structure remained unchanged, because both techniques depend on GMP-regulated laboratory expansion that cannot be compressed into a single theatre visit.

That structure carries genuine costs. Patients face two separate anaesthetics and two separate recoveries. Between biopsy and implantation lies a 3-to-6-week cell-expansion window during which the defect is unprotected and may enlarge; the cultured cells can also dedifferentiate over that interval, potentially affecting repair-tissue quality. Under NICE commissioning, the full pathway runs to approximately £16,000 per patient. Rehabilitation after the second procedure typically extends from 6 to 18 months, regardless of which variant is used.

None of this diminishes what the evidence record represents — it is the benchmark every newer approach must clear. But the structural limitations are well-characterised, and they are precisely the problems that a single-stage model such as STACI is designed to resolve.

How STACI works

During a STACI procedure, everything happens within a single unbroken operation. The surgeon takes a small cartilage sample from a non-weight-bearing area of the knee and a separate bone-marrow aspirate from the same operative field. Both are processed immediately: an enzymatic digestion step frees the chondrocytes from their surrounding matrix without altering their character, while the bone-marrow fraction is concentrated to isolate mesenchymal stem cells (MSCs). The two populations are then combined and co-seeded onto a type I/III collagen scaffold before implantation into the defect — all without the patient leaving theatre.

This sequence directly targets two recognised weaknesses of laboratory expansion. The first is dedifferentiation: chondrocytes cultured in a lab for three to six weeks progressively lose the molecular markers — collagen II, aggrecan, Sox9 — that make them effective cartilage-repair cells. By seeding the cells onto the scaffold within minutes of harvest, STACI bypasses that shift entirely. The second weakness is the unprotected interval: in the standard model the defect remains exposed for weeks between biopsy and implantation; STACI eliminates that window.

The MSC contribution adds something the conventional two-stage model does not include: a regenerative signal from the patient's own bone marrow that may support graft integration and tissue maturation.

One distinction is worth stating clearly. AMIC — autologous matrix-induced chondrogenesis — is sometimes grouped alongside single-stage options, but it works through marrow stimulation rather than harvested chondrocytes. STACI is a chondrocyte-plus-MSC procedure; AMIC is not. The biological difference is substantial, and conflating the two misrepresents what each technique is actually delivering to the repair site.

What the clinical evidence actually shows

The closest thing to controlled STACI-specific data comes from the Ortho-ACI™ study published by Crowe in 2015. In 15 patients with 25 chondral defects, chondrocytes seeded intraoperatively onto a type I/III collagen scaffold achieved 97% cell retention at 20 minutes and 99% at 90 minutes. Crucially, the molecular profile at the point of implantation was more consistent with native primary chondrocytes than with cells that had undergone standard 4-day preoperative seeding — a finding that directly supports the dedifferentiation argument set out in the previous section.

Clinical follow-up was promising. Arthroscopic assessment at a mean 17 months showed good or excellent repair in 83% of cases. Of the smaller imaging subset evaluated at a mean 25 months, MRI graded all assessed grafts as good or excellent. Edge tissue overgrowth occurred in 29% of cases — seven of twenty-four grafts — but six of those seven were still scored arthroscopically excellent, suggesting the complication affected cosmetic appearance of the repair more than its structural quality. This warrants disclosure, not alarm.

What the study cannot provide is certainty at scale: 15 patients is a proof-of-concept series, not a Phase III trial.

Broader single-stage reviews by Runer (2022) and Dasari (2023) extend the picture. Aggregating techniques including CAIS and minced cartilage approaches, they report statistically significant KOOS and IKDC improvements from 3–6 months, sustained at two years, and superiority over microfracture in randomised trials. Histological analyses indicate a high proportion of hyaline-like repair tissue. These results are encouraging for the single-stage concept as a category, but they aggregate heterogeneous methods — not STACI's specific enzymatic-plus-MSC model — so they cannot substitute for a direct comparison.

No Phase III randomised controlled trial currently pits STACI against two-stage MACI or ACI. The evidence ladder is real, and the next rung — a head-to-head trial — has not yet been built.

The hidden cost of the first biopsy stage

Numbers from real-world practice add a different dimension to this debate. In a multisurgeon case series, only 12 of 46 patients — 26.1% — who underwent an arthroscopic biopsy for planned ACI or MACI ultimately proceeded to cell implantation. For the majority, arthroscopic debridement, chondroplasty, or loose body removal performed at that first visit was sufficient to relieve symptoms adequately.

This is not a failure of surgical judgement. It reflects a structural feature of the two-stage model: a biopsy-only visit that involves a real anaesthetic, a real recovery, and a tissue harvest, yet results in no restorative implantation for nearly three-quarters of patients who undergo it.

That observation does not undermine ACI's value for the patients who genuinely need it — the evidence for those cases remains strong. What it does challenge is the assumption that a stand-alone first stage is a reliable and efficient gateway. If the defect can be assessed and addressed in one visit, a single-stage approach removes the uncertainty entirely: those who would have recovered from debridement alone, and those who require restorative repair, are both managed within the same theatre sitting rather than separated by weeks of waiting.

Where STACI stands today and what to ask at assessment

The position STACI occupies is best understood through two overlapping constraints: evidence maturity and regulatory classification — and neither resolves quickly.

The clinical data reviewed above — Crowe 2015, Level IV feasibility, no Phase III RCT — means STACI has not cleared the bar required for routine commissioning under UK practice guidelines. NICE TA477 governs cartilage repair commissioning on the basis of the two-stage model; a technique that bypasses GMP/GLP laboratory cell expansion sits outside that framework by design. In many jurisdictions STACI remains classified as investigational — not because the biology is in doubt, but because the patient-safety mechanisms built around standard ACI were designed for a pathway that includes laboratory oversight. That is a genuine constraint, not a bureaucratic formality, and it shapes where access is currently possible: research programmes, registry-based pathways, or specialist centres formally tracking outcomes.

Patients who would qualify for ACI or MACI — focal ICRS grade III–IV lesions, typically 2–10 cm², in younger active patients without prior cartilage surgery — are the same group for whom STACI would be considered if available. At specialist assessment the most useful questions go beyond eligibility: does this centre offer STACI within a governed research or registry framework, with formal outcome tracking? If not, which licensed cell-based pathway is currently commissioned for this specific defect size and location, and what does its evidence base look like for that configuration? Those questions distinguish structured access from an unvalidated offer.

Clinicians working in cartilage preservation in the UK have contributed to shaping how these distinctions are drawn. Taylor and Lee's 2019 paper, which described STACI explicitly as the next generation of ACI, both makes the biological case and places the evidence deficits on record — a useful orientation for any patient navigating this space. For those at the appropriate decision stage, a consultation at the London Cartilage Clinic is a reasonable first step toward establishing which pathway applies.